05  Apr 18

DRONET-M


DR SANJAY AGRAWAL
LEADING PHARMACEUTICAL CONSULTANT AND EDITOR-IN CHIEF OF IJMTODAY




EACH TABLET CONTAINS:

- Drotaverine HCL 80 mg
- Mefenamic Acid 250 mg

DESCRIPTION

DRONET-M Tablet is a combination of Drotaverine HCL and Mefanamic Acid.

Drotaverine is classified as selective phosphodiesterase inhibitor and acts as antispasmodic prescribed for pain and dysfunction caused by smooth muscle spasm.

Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that alleviates pain symptoms by inhibition of pain mediators associated with both isoforms of COX and prevents formation of prostaglandins and is used to treat mild to moderate pain, including menstrual pain, and is sometimes used to prevent migraines associated with menstruation.

INDICATIONS

DRONET-M is indicated mainly for the treatment of biliary tract, gastrointestinal, urinary tract spasm, and pain due to primary dysmenorrhea.

DOSAGE & ADMINISTRATION

The adult oral dose of DRONET-M is one tablet taken every 6-8 hours for more than 2-3 days. The dose for children more than 14 years is same as adult dose. The formula is best taken with a full glass of water or with food.

CONTRAINDICATIONS

DRONET-M should not be administered in the following cases:

- DRONET-M is not recommended in asthma patients, individuals whom have history of GI (Gastrointestinal) bleeding, patients with renal impairment, individuals with hypersensitivity.

PRECAUTIONS

Caution should be exercised when DRONET-M is prescribed at the same time with Magnesium hydroxide cause increase in drug absorption.

Caution should be exercised when prescribing DRONET-M to patients with lithium toxicity as it increases lithium toxicity which can be fatal.

DRONET-M contains drotaverine for which dosage adjustments may be required in patients with renal impairment since drotaverine and its metabolites are excreted by kidneys.

Drotaverin has the potential to decrease the antiparkinsonian effect of levodopa resulting in increase in rigidity and tremor. In patients of parkinson DRONET-M is not recommended.

ADVERSE EFFECTS

The most frequently reported adverse reactions associated with the use of mefenamic acid are diarrhea, nausea with or without vomiting, and abdominal pain. Other GI reactions less frequently reported include anorexia, pyrosis, flatulence and constipation. GI ulceration with and without hemorrhage can also occur with mefenamic acid. Oral drotaverine has very less adverse event incidence reported.

PREGNANCY & LACTATON

DRONET-M should not to be used in pregnancy. The use of mefenamic acid in late pregnancy is not recommended because of the effects on the fetal cardiovascular system of drugs of this class. There are no controlled data in human pregnancy. Mefenamic acid is only recommended for use during pregnancy when benefit outweighs risk.

PRESENTATION

DRONET-M tablets are available in a 10X10s blister packing

  Miss. Vanita

07 Apr 2018
Very nice product


POST COMMENT

Your email address will not be published. Required fields are marked *